X4 Pharmaceuticals’ (XFOR) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research note published on Wednesday,Benzinga reports. They currently have a $3.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock opened at $0.25 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The company has a market capitalization of $43.42 million, a PE ratio of -2.78 and a beta of 0.39. The company has a 50 day moving average price of $0.43 and a 200-day moving average price of $0.52. X4 Pharmaceuticals has a fifty-two week low of $0.24 and a fifty-two week high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million. As a group, equities analysts forecast that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 over the last 90 days. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the business. Cantor Fitzgerald L. P. acquired a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $30,000. Verition Fund Management LLC acquired a new stake in X4 Pharmaceuticals in the third quarter worth about $30,000. Atria Wealth Solutions Inc. purchased a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth about $44,000. Wells Fargo & Company MN increased its holdings in shares of X4 Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock valued at $58,000 after acquiring an additional 26,763 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.